Can You Build Muscle on Retatrutide? The Testosterone Confound in Viral Transformations

Search "retatrutide results" and you will find dramatic before-and-after posts: people who lost a third of their body weight and emerged visibly muscular, lean, and vascular — not "deflated." It is tempting to conclude that retatrutide builds or preserves muscle in a way other weight-loss drugs do not.

It does not. Retatrutide is a weight-loss drug, not an anabolic one. The striking physiques in the most-shared transformations are almost always built by what else is in the protocol — most often testosterone and growth-hormone peptides — while retatrutide does the job it was designed for: driving the scale down. This page separates the two, using one of the most-viewed transformation posts as a worked example.

A worked example: the viral 7-month transformation

In June 2026, a 7-month retatrutide transformation log went viral on X, viewed more than 400,000 times. The headline numbers were genuinely impressive:

Start (Dec 2025): 215 lb, ~21% body fat, 38" waist. Now: 178 lb, 7.9% body fat, 29.25" waist. Roughly 1.4 lb/week across the full run.

To the poster's credit, he did not present this as a clean drug result. Buried in the same thread, he listed every lever he was pulling — and explicitly noted: "This was not a Reta clinical trial. It was one piece of a full biohacking protocol." That transparency is exactly what makes it a useful teaching case. The full stack:

Read that table and the "muscular at 7.9% body fat" outcome stops being mysterious. Four of the six compounds act on muscle and growth-hormone pathways. Retatrutide is not one of them.

What retatrutide actually does to muscle

Retatrutide is a triple agonist (GIP, GLP-1, glucagon) that produces weight loss by suppressing appetite and increasing energy expenditure. Like all weight loss — from any drug, surgery, or diet — some of the weight lost is lean tissue, not just fat.

In the Phase 2 DXA sub-study (Coskun et al., Lancet Diabetes & Endocrinology 2025), fat accounted for roughly 62.0% to 69.3% of total weight lost across the effective retatrutide doses — meaning 30.7% to 38.0% came from lean mass. That ratio is comparable to semaglutide (~39% lean in STEP 1) and tirzepatide (~25–33% lean in SURMOUNT-1). Retatrutide does not preserve muscle better than other GLP-1-based drugs, and it has no mechanism to build it.

So on retatrutide alone, the honest expectation is: you lose fat, you lose some muscle along with it, and a disciplined person with resistance training and high protein intake keeps that lean loss toward the lower end of the range. You do not come out the other side more muscular than you went in. For the full body-composition data, see Does Retatrutide Cause Muscle Loss?.

The testosterone confound

This is the part the transformation photos hide. Testosterone, especially at the high-replacement-to-supraphysiological doses common in biohacking protocols, increases lean mass on its own — independent of training or diet.

The clearest evidence is the Bhasin testosterone dose-response trial (Am J Physiol Endocrinol Metab, 2001), which held energy and protein intake constant and gave healthy men graded weekly testosterone doses for 20 weeks:

Fat-free mass rose dose-dependently, and the change correlated tightly with testosterone concentration. The viral example's 200 mg/week sits between the 125 mg and 300 mg arms — so roughly 4 to 5 kg of lean mass gain is expected from the testosterone alone, before counting the additional GH/IGF-1 support from CJC-1295, ipamorelin, and tesamorelin.

Put the two drugs side by side and the division of labor is clean:

His weight-loss numbers actually validate retatrutide rather than overstate it. A ~17% total loss at an average of roughly 2 mg/week, over about 30 weeks, tracks neatly between the −8.7% (1 mg) and −17.1% (4 mg) figures from the NEJM Phase 2 trial at 48 weeks. The poster himself said reta "for sure helped with the weight loss as the main driver" — he did not claim it built the muscle.

The negatives, by contrast, are retatrutide

If you want to know what retatrutide alone contributed to this protocol, look at the side effects — because those track the drug, not the stack. The same log reported:

• Resting heart rate climbing from the mid-50s to the low-70s, which persisted even after dropping to 1 mg
• Decreased sleep quality
• A flat, apathetic mood when the dose was pushed to 2.5 mg

The heart-rate signal is textbook retatrutide. The NEJM Phase 2 trial documented dose-dependent increases in heart rate that peaked at 24 weeks, and elevated resting heart rate is one of the most consistently reported retatrutide effects. These were significant enough that the poster cited them as his reason to switch off retatrutide entirely. For the full safety picture, see Retatrutide Side Effects.

What this means if you are considering retatrutide

• If you are not on testosterone or GH peptides, do not expect a "transformation-post" physique. Those results are a stacked protocol, not a retatrutide result. Comparing yourself to them sets a false benchmark.
• Retatrutide will not build muscle. Its honest job is fat loss. The best you can do for muscle on retatrutide alone is minimize lean loss — through resistance training and high protein intake — not add to it.
• The dramatic body-composition numbers in viral posts usually have an anabolic agent behind them, even when it is not in the headline. Read the full thread before you read the photos.
• Stacking retatrutide with testosterone is a medical decision, not a hack. It combines a drug that raises heart rate with weight loss, supraphysiological hormone dosing, and injectable peptides — and is well outside any studied regimen. None of the compounds above are FDA-approved for this use.

Frequently Asked Questions

Sources

• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Coskun, T., et al. (2025). Retatrutide body composition sub-study (DXA). The Lancet Diabetes & Endocrinology. Article
• Bhasin, S., et al. (2001). Testosterone dose-response relationships in healthy young men. American Journal of Physiology-Endocrinology and Metabolism. DOI: 10.1152/ajpendo.2001.281.6.E1172
• Viral 7-month retatrutide transformation log (X, June 2026; over 400,000 views) — cited as an illustrative example of how multi-compound protocols confound the interpretation of single-drug results.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency. Testosterone, HCG, and growth-hormone peptides are not approved for weight management or body recomposition.

The transformation referenced on this page is used solely as an illustrative example of how multi-compound protocols confound the interpretation of single-drug results. Nothing here endorses, recommends, or instructs the use of any of these compounds in combination.

Do not make decisions about your health, or combine any of these compounds, without consulting a qualified healthcare provider. Do not purchase or self-administer grey-market peptides based on social media posts or any information on this site.